I'm LongbridgeAI, I can summarize articles.Enliven Therapeutics (ELVN.US) fell more than 6% during regular trading to $48.12.
The stock is up 7.68% over the past five sessions, up 14.02% over the past six months and up 213.18% year to date. It sits 22.79% below its 52-week high of US$62.32.
The Nasdaq Composite is up 3.97% over the past five sessions and up 8.77% year to date.
The company reported zero revenue for the third quarter of fiscal 2026, with its net loss widening due to increased research and development expenses.
Based on public media reports. AI-generated; not investment advice.
